US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DOGWOOD THERAPEUTICS INC

4.89

+0.00500.10%

Post-market: 4.80-0.0883-1.81%19:23 EDT

Volume:58.82K

Turnover:288.71K

Market Cap:9.35M

PE:-0.39

High:5.16

Open:5.10

Low:4.71

Close:4.89

Loading ...

Overview Company News Filings

Dogwood Therapeutics Reports Q2 2025 Results: Sales Surpass Expectations, EPS Beats Forecast

BRIEF-Dogwood Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing

Dogwood files $150M mixed securities shelf

Press Release: Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics Inc expected to post a loss of $2.37 a share - Earnings Preview

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral

MT Newswires Live

Dogwood Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings

BRIEF-Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

THOMSON REUTERS

DWTX: Interim Data for Phase 2b Trial in 4Q25…

Zacks Small Cap Research

BRIEF-Dogwood Therapeutics Regains Nasdaq Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

THOMSON REUTERS

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Press Release: Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Ten option delistings on March 24th

Dogwood Therapeutics: Announces Dosing of First Patient in Phase 2B Trial Evaluating Halneuron in Patients With Chemotherapy-Induced Neuropathic Pain

THOMSON REUTERS

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/DWTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":4.89,"timestamp":1749240000000,"preClose":4.885,"halted":0,"volume":58816,"hourTrading":{"tag":"盘后","latestPrice":4.8017,"preClose":4.89,"latestTime":"19:23 EDT","volume":554,"amount":2664.2356,"timestamp":1749252236410},"delay":0,"floatShares":1332178,"shares":1911128,"eps":-12.516033,"marketStatus":"Market Closed","change":0.005,"latestTime":"06-06 16:00:00 EDT","open":5.1,"high":5.16,"low":4.7101,"amount":288711.51078400004,"amplitude":0.092098,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.516033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":4.885,"preHourTrading":{"tag":"盘前","latestPrice":5.18,"preClose":4.85,"latestTime":"09:29 EDT","volume":1633,"amount":8012.087513,"timestamp":1749216552560},"postHourTrading":{"tag":"盘后","latestPrice":4.8017,"preClose":4.89,"latestTime":"19:23 EDT","volume":554,"amount":2664.2356,"timestamp":1749252236410},"volumeRatio":0.8651243806800806},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":1332178,"roa":"-19.14%","roe":"-51.48%","lyrEps":-12.516033,"volumeRatio":0.8651243806800806,"shares":1911128,"dividePrice":0,"high":5.16,"amplitude":0.092098,"preClose":4.885,"low":4.7101,"week52Low":1.62,"pbRate":"-0.52","week52High":29.28,"institutionHeld":0,"latestPrice":4.89,"eps":-12.516033,"divideRate":0,"volume":58816,"delay":0,"ttmEps":-12.516033,"open":5.1,"prevYearClose":2.49,"prevWeekClose":5.18,"prevMonthClose":5.18,"prevQuarterClose":5.01,"fiveDayClose":5.18,"twentyDayClose":4.56,"sixtyDayClose":10.7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539294851","title":"Dogwood Therapeutics Reports Q2 2025 Results: Sales Surpass Expectations, EPS Beats Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2539294851","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539294851?lang=en_us&edition=fundamental","pubTime":"2025-05-30 07:13","pubTimestamp":1748560429,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. has not released specific financial results in the provided document. However, a significant update involves a strategic transaction completed in Q4 2024, where Dogwood acquired Pharmagesic Holdings, including its novel pain development candidate, Halneuron. As part of this transaction, CKLS, a publicly listed company on the Hong Kong exchange, received 211,383 shares of Common Stock and 2,108.3854 shares of Series A Preferred Stock, which is convertible into 10,000 shares of common stock each, pending shareholder approval. Additionally, a $20 million strategic financing loan from an affiliate of CK Life Sciences International was converted into 284.2638 shares of Series A-1 Preferred Stock in Q1 2025. Upon conversion of the Preferred Stock, CKLS and its affiliates will hold approximately 90% of Dogwood's common stock on a fully diluted basis. No specific guidance or outlook for sales, revenue, or profits has been disclosed in the document.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL74Ggrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00775","DWTX"],"gpt_icon":0},{"id":"2537150275","title":"BRIEF-Dogwood Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537150275","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537150275?lang=en_us&edition=fundamental","pubTime":"2025-05-24 06:29","pubTimestamp":1748039389,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - SEC FilingDogwood Therapeutics Inc DWTX.O:DOGWOOD THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILINGSource text: [ID:n0001104659-25-052506]Further company coverage: DWTX.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV2PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2537508831","title":"Dogwood files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2537508831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537508831?lang=en_us&edition=fundamental","pubTime":"2025-05-24 05:30","pubTimestamp":1748035813,"startTime":"0","endTime":"0","summary":"17:27 EDT Dogwood (DWTX) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-files-150m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2533180118","title":"Press Release: Dogwood Therapeutics Announces First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533180118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533180118?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:00","pubTimestamp":1746709200,"startTime":"0","endTime":"0","summary":"- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Study -. - Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 -. - Cash on hand of $17.5M provides operational runway through Q1 2026 -. ATLANTA, May 08, 2025  -- Dogwood Therapeutics, Inc.  , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025.\"There are no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment,\" said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. \"We believe Halneuron's clinically significant effects in treating both general cancer pain and chemotherapy induced neuropathic pain highlights the great potential to expand our Na 1.7 research pipeline to other forms of pain, including diabetic peripheral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LENZ","LU1236620750.USD","LU0823421333.USD","LU1037948541.HKD","LU1236620834.HKD","LU0251132253.USD","SG9999014914.USD","IE00B1BXHZ80.USD","LU0345774631.USD","LU1934455277.USD","LU1934455194.USD","LU1642822529.SGD","LU2264538146.SGD","LU2023250504.SGD","LU0426412945.USD","LU0348723411.USD","SG9999000418.SGD","LU0823417653.USD","BK4022","LU0476273544.USD","NQmain","LU0225283273.USD","LU1035775433.USD","R","LU0265550946.USD","LU0097036916.USD","SG9999018857.SGD","LU0942090050.USD","SG9999001424.SGD","LU0215105999.USD","LU1670627923.USD","LU2097829019.USD","LU2360032135.SGD","BK4106","LU0823421416.USD","LU1623119135.USD","SG9999017495.SGD","DWTX","LU2326559502.SGD","LU0689626769.HKD","LU0106261372.USD","LU0417517546.SGD","LU1917777945.USD","LU2111349929.HKD","LU2028103732.USD","LU0079474960.USD","LU0234570918.USD","LU2125154778.USD"],"gpt_icon":1},{"id":"2533393581","title":"Dogwood Therapeutics Inc  expected to post a loss of $2.37 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533393581","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533393581?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:47","pubTimestamp":1746449225,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc  expected to post a loss of $2.37 a share - Earnings Preview Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX"],"gpt_icon":0},{"id":"2532707409","title":"Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532707409","media":"Newsfile","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532707409?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102600,"startTime":"0","endTime":"0","summary":"Alpharetta, Georgia-- - Dogwood Therapeutics, Inc. , today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Greg Duncan, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. .To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.D. Boral Capital is a leader on Wall Street, having aggregated over $25 billion in capital across approximately 350 transactions through various product types.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dogwood-therapeutics-inc-announces-participation-123000685.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dogwood-therapeutics-inc-announces-participation-123000685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","DWTX","BK4588","BK4139","BK4585","BK4561","BK4581","ET","BK4007","BK4144","LENZ"],"gpt_icon":0},{"id":"2529501465","title":"HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2529501465","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529501465?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:44","pubTimestamp":1745408669,"startTime":"0","endTime":"0","summary":"HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DWTX","LENZ"],"gpt_icon":0},{"id":"2529031445","title":"Dogwood Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529031445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529031445?lang=en_us&edition=fundamental","pubTime":"2025-04-23 18:58","pubTimestamp":1745405880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DWTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2025 06:58 ET (10:58 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DWTX"],"gpt_icon":0},{"id":"2529800742","title":"Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800742","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800742?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:21","pubTimestamp":1745245300,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44899271/nasdaq-tumbles-over-400-points-netflix-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NFLX","LXEH","DWTX","AREB","PCOM","NDAQ","SHFS","UPXI","AIEV",".IXIC"],"gpt_icon":1},{"id":"2526669811","title":"BRIEF-Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2526669811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526669811?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:29","pubTimestamp":1744378160,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of ComplianceApril 11 (Reuters) - Dogwood Therapeutics Inc DWTX.O:DOGWOOD THERAPEUTICS, INC. RECEIVES NASDAQ CONFIRMATION OF COMPLIANCESource text: ID:nGNX4y8qrLFurther company coverage: DWTX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2526983276","title":"Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2526983276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526983276?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:15","pubTimestamp":1744377310,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2525373436","title":"DWTX: Interim Data for Phase 2b Trial in 4Q25…","url":"https://stock-news.laohu8.com/highlight/detail?id=2525373436","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525373436?lang=en_us&edition=fundamental","pubTime":"2025-04-04 22:42","pubTimestamp":1743777720,"startTime":"0","endTime":"0","summary":"First Patient Dosed in Phase 2b Trial of Halneuron. Halneuron , a sodium channel blocker, was originally discovered in the pufferfish and subsequent research has identified the toxin in 13 phyla  that includes both marine and terrestrial eukaryotes . As a natural poison, TTX is extremely effective and is the most potent non-peptide neurotoxin known. It blocks the influx of sodium through voltage-gated sodium channels , thereby preventing the initiation and propagation of action potentials in almost all neurons and muscle cells .This was a randomized, double blind, parallel design, multicenter trial that enrolled 165 patients with moderate to severe inadequately controll","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dwtx-interim-data-phase-2b-144200591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2524254063","title":"BRIEF-Dogwood Therapeutics Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254063","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254063?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:03","pubTimestamp":1743685433,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics Regains Nasdaq ComplianceApril 3 (Reuters) - Dogwood Therapeutics Inc DWTX.O:DOGWOOD THERAPEUTICS, INC. REGAINS NASDAQ COMPLIANCESource text: ID:nGNXbvbtFqFurther company coverage: DWTX.O (((( Reuters.briefs@thomsonreuters.com ;));))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2524540812","title":"Dogwood Therapeutics, Inc. Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2524540812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524540812?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:03","pubTimestamp":1743685402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2524257609","title":"Dogwood Therapeutics, Inc. Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2524257609","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524257609?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:00","pubTimestamp":1743685200,"startTime":"0","endTime":"0","summary":"ATLANTA, April 03, 2025  -- Dogwood Therapeutics, Inc.  , a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550.DWTX Chairman and CEO Greg Duncan stated, “We appreciate the consideration Nasdaq has shown Dogwood Therapeutics, Inc.” He continued, “The Company has a strong cash position of $17.5 million as of the end of Q1, with no debt, better positioning the Company to advance its continued mission to build shareholder value.”Dogwood Therapeutics  is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV1.7 analgesic program is centere","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dogwood-therapeutics-inc-regains-nasdaq-130000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","LU2210150020.SGD","BK4588","IE00BGHQF748.EUR","QLD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","LU2210149790.SGD","DWTX","MNQmain","USAW.SI",".IXIC","LENZ","NVIW.SI","PSQ","NQmain","BK4112","QID","IE00B64PRP62.GBP","USJW.SI","SQQQ","BK4585","BK4139","TQQQ"],"gpt_icon":1},{"id":"2524971997","title":"Press Release: Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524971997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524971997?lang=en_us&edition=fundamental","pubTime":"2025-04-01 03:45","pubTimestamp":1743450300,"startTime":"0","endTime":"0","summary":"-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron Chemotherapy Induced Neuropathic Pain  Phase 2b Trial -. - Halneuron CINP P2b study interim data readout is expected in Q4 2025 -. - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward -. - Capital raise provides operational runway through Q1 2026 -. ATLANTA, March 31, 2025  -- Dogwood Therapeutics, Inc.  , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024.\"We have made considerable progress in advancing our flagship Halneuron CINP Phase 2b study, with interim data expected by year end. We have also significantly improved our balance sheet and liquidity over the past few months, improving our cash position in a recent capital raise along with the agreement of our largest shareholder to exchange all their outstanding loan ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827781.USD","LU2361045086.USD","LU0354030438.USD","LU2404859741.USD","LU0348723411.USD","LU2361044949.HKD","LU0957791311.USD","BK4535","LU0061474960.USD","LU0426417589.USD","LU2023251221.USD","LU2404859667.USD","BK4581","LU0690374961.EUR","LU0289961442.SGD","LU1623119135.USD","LU1791710400.SGD","BK4227","LU0225283273.USD","LU0345774391.USD","LU0069063385.USD","LU0957808578.USD","LU2264538146.SGD","BK4232","LU0823421333.USD","LENZ","DWTX","SG9999014906.USD","LU1934455277.USD","LU0823417653.USD","LU2089284900.SGD","IE00B19Z9505.USD","LU0950375773.USD","SG9999014880.SGD","LU1934455863.HKD","BK4585","LU0124676726.USD","LU1691799644.USD","LU2028103732.USD","LU1366333091.USD","LU2242649171.HKD","R","IE00BZ1G4Q59.USD","LU0672654240.SGD","LU0345774631.USD","LU1642822529.SGD","LU0057025933.USD","LU2097829019.USD","LU2087625088.SGD"],"gpt_icon":1},{"id":"2521163723","title":"Ten option delistings on March 24th","url":"https://stock-news.laohu8.com/highlight/detail?id=2521163723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521163723?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:37","pubTimestamp":1742819831,"startTime":"0","endTime":"0","summary":"Option delistings effective March 24th include Aligos Therapeutics (ALGS), Allbirds (BIRD), Biotricity Inc (BTCY), DWTX Stock (DWTX), Dixie Group I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ten-option-delistings-on-march-24th?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ten-option-delistings-on-march-24th?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4505","BTCmain","BK4139","XBTmain","BIRD","BTCY","ALGS","BK4146","BK4167"],"gpt_icon":0},{"id":"2520676522","title":"Dogwood Therapeutics: Announces Dosing of First Patient in Phase 2B Trial Evaluating Halneuron in Patients With Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676522?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:47","pubTimestamp":1742302047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q102E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2520671382","title":"Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2520671382","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520671382?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:45","pubTimestamp":1742301900,"startTime":"0","endTime":"0","summary":"Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market. ATLANTA, March 18, 2025  -- Dogwood Therapeutics, Inc.  , a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP , evaluating Halneuron for the treatment of neuropathic pain associated with prior chemotherapy treatment .“Halneuron is being developed to specifically inhibit the NaV 1.7 sodium channel, given the well-established role of this target in pain transmission,” said Greg Duncan, Dogwood’s Chairman and Chief Executive Officer. “We believe Halneuron’s inherent specificity and potency may enable physicians to use very low doses of Halneuron to both reduce pain and minimize the off-target effects that have limited prior NaV 1.7 development candidates.”Dogwood’s antiviral program includes IMC-1 and IMC-2, which a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dogwood-therapeutics-announces-dosing-first-124500144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","DWTX"],"gpt_icon":0},{"id":"2520601785","title":"DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…","url":"https://stock-news.laohu8.com/highlight/detail?id=2520601785","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520601785?lang=en_us&edition=fundamental","pubTime":"2025-03-18 18:44","pubTimestamp":1742294640,"startTime":"0","endTime":"0","summary":"On March 18, 2025, Dogwood Therapeutics, Inc.  announced that the first patient was dosed in the Phase 2b HALT-CINP . This is a four-week study that will examine the safety and efficacy of Halneuron in patients with moderate-to-severe CINP. The primary efficacy endpoint is the change from baseline at Week 4 in the weekly average of daily 24-hour recall pain intensity scores, which will be recorded in e-diaries on participants’ smartphones. Secondary efficacy endpoints include Patient Global Impression of Change , PROMIS Fatigue, PROMIS Sleep, PROMIS-29, Pain Interference, Hospital Anxiety and Depression Scale , and Neuropathic Pain Symptom Inventory . The target enrollment is currently 200 patients, which is subject to adjustment following a planned interim readout in the fourth quarter of 2025 following enrollment of 100 patients. The interim analysis will allow for changes to the study, if necessary, to improve trial outcomes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dwtx-first-patient-dosed-phase-104400186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DWTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"DWTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-4.21},{"market":"US","date":"2025-03-31","symbol":"DWTX","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-6.29},{"market":"US","date":"2024-10-09","symbol":"DWTX","defaultRemindTime":1728480600000,"type":"split","dateTimestamp":1728446400000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2024-08-08","symbol":"DWTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.05},{"market":"US","date":"2024-05-09","symbol":"DWTX","fiscalQuarterEnding":"2024/03","expectedEps":-0.08,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2025-06-06","current":-0.424679,"percent":0.932099,"low":-4.048873,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"high":-0.317141,"avg":-0.974918,"sd":0.714706,"marketCap":9335860},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860}],"updateTime":1749302699602}}}